Biotechnology

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

With over $1B in cash, Nektar is pushing its novel drug, rezpegaldesleukin, into final trials. It's a high-stakes bet on a new era for autoimmune care.

A biotech startup's nomination for a top award validates its unique platform, which uses a patient's own cells to fight cancer and prepare for future pandemics.

Inhibrx Biosciences lands a massive new loan to fuel its promising cancer drug trials, but rising costs and a wider net loss paint a high-stakes picture.

With mounting losses and a CEO's unyielding optimism, activist investors issue an ultimatum: take proteomics firm Seer private or face the consequences.

How a startup, once dismissed as 'too niche,' leveraged deep science to achieve 1,624% growth, proving the microbiome is the next frontier of medicine.

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Abeona Therapeutics celebrates rising sales for its life-changing RDEB therapy, ZEVASKYN. But behind the numbers lies a story of manufacturing hurdles and mounting debt.

Facing a 'going concern' warning, Pulmatrix abandons its drug pipeline for a reverse merger, betting its survival on the high-risk field of longevity science.

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.

With promising data for its GX-03 cream in an underserved patient group, Turn Therapeutics expands its trial, hires an ex-FDA head, and eyes a new disease.

With pivotal data due in September, Connect Biopharma's rademikibart could redefine acute asthma and COPD care. Can it navigate this clinical tightrope?

BioCardia secures key regulatory backing in the US and Japan, but the real story may be its pivot to a platform provider for the entire cardiac biologics field.

With key FDA backing and promising clinical data, Allogene Therapeutics is advancing a vision where complex cell therapies are not just for major medical centers.